传导系统起搏时代下的房室结消融治疗房颤
本文综述了在传导系统起搏新技术背景下,房室结消融(AVNA)联合永久起搏器植入治疗持续性房颤的作用。文章讨论了房颤的血流动力学后果、「起搏并消融」疗法改善预后的机制,分析了不同起搏方法的历史与近期文献,并识别可能从早期实施该策略中获益的患者群体。
要点
- 传导系统起搏可克服AVNA后起搏诱导的心肌病,使AVNA重新成为房颤治疗选择
- 持续性房颤经重复消融和抗心律失常药后长期窦律维持率仍有限
- AVNA联合起搏的「起搏并消融」策略可能使特定患者群体获益
核心结论
- 在传导系统起搏时代,房室结消融联合永久起搏器植入重新成为持续性房颤的有价值治疗选择。
研究设计与样本
- 本文为综述,分析不同起搏方法下房室结消融治疗房颤的历史与近期文献。
主要发现
- 持续性房颤患者即使经重复消融和抗心律失常药物,长期维持窦律的可能性仍有限。
- 传导系统起搏的应用使AVNA后起搏诱导的心肌病被认为得以克服。
临床怎么用
- 对持续性房颤经消融和药物仍难以维持窦律的患者,可考虑AVNA联合传导系统起搏。
- 需识别可能从早期实施「起搏并消融」策略中获益的患者群体。
局限性
- 本文为综述,未报告原始研究的具体样本量、效应量或置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite key advances in catheter-based treatments, the management of persistent atrial fibrillation (AF) remains a therapeutic challenge in a significant subset of patients. While success rates have improved with repeat AF ablation procedures and the concurrent use of antiarrhythmic drugs, the likelihood of maintaining sinus rhythm during long-term follow-up is still limited. Atrioventricular node ablation (AVNA) has returned as a valuable treatment option given the recent developments in cardiac pacing. With the advent of conduction system pacing, AVNA has seen a revival where pacing-induced cardiomyopathy after AVNA is felt to be overcome. This review will discuss the role of permanent pacemaker implantation and AVNA for AF management in this new era of conduction system pacing. Specifically, this review will discuss the haemodynamic consequences of AF and the mechanisms through which 'pace-and-ablate therapy' enhances outcomes, analyse historical and more recent literature across various pacing methods, and work to identify patient groups that may benefit from earlier implementation of this approach.
引用
- Joza J, Burri H, Andrade JG, et al. Atrioventricular node ablation for atrial fibrillation in the era of conduction system pacing. Eur Heart J. 2024. PMID: 39397777. doi:10.1093/eurheartj/ehae656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。